DEA Moves to Schedule Four Emerging Synthetic Opioids
The Brorphine Schedule I process is moving forward as DEA targets four emerging synthetic opioids for temporary federal control. The drugs are appearing in illicit drug seizures and toxicology testing, including fatal cases involving cychlorphine. The…
Management of Opioid Withdrawal Syndrome and Opioid Dependence Treatment
Opioid withdrawal management is critical in cases involving synthetic opioid contamination such as protonitazene. This case report highlights the need for adjusted buprenorphine dosing. Effective opioid dependence treatment requires awareness of these…
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
Nitazene synthetic opioids such as N-pyrrolidino metonitazene and N-pyrrolidino protonitazene have been temporarily placed in Schedule I. These substances pose significant overdose risks and are emerging threats in illicit drug supplies. Clinicians…